Beta

Co-diagnostics, inc.CODX.US Overview

US StockHealthcare
(No presentation for CODX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CODX AI Insights

CODX Overall Performance

CODX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CODX Recent Performance

-1.21%

Co-diagnostics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

CODX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CODX's Trend

CODX Key Information

CODX Valuation Metrics

CODX Profile

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Price of CODX

CODX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CODX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-42.01
PE Ratio (TTM)
-
Forward PE
15.36
PS Ratio (TTM)
9.66
PB Ratio
0.29
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.28%
Net Margin
-7533.62%
Revenue Growth (YoY)
-84.10%
Profit Growth (YoY)
-86.28%
3-Year Revenue Growth
-42.68%
3-Year Profit Growth
-69.81%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-42.01
PE Ratio (TTM)
-
Forward PE
15.36
PS Ratio (TTM)
9.66
PB Ratio
0.29
Price-to-FCF
-
Gross Margin
64.28%
Net Margin
-7533.62%
Revenue Growth (YoY)
-84.10%
Profit Growth (YoY)
-86.28%
3-Year Revenue Growth
-42.68%
3-Year Profit Growth
-69.81%
  • When is CODX's latest earnings report released?

    The most recent financial report for Co-diagnostics, inc. (CODX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CODX's short-term business performance and financial health. For the latest updates on CODX's earnings releases, visit this page regularly.

  • What is the operating profit of CODX?

    According to the latest financial report, Co-diagnostics, inc. (CODX) reported an Operating Profit of -26.54M with an Operating Margin of -10,056.68% this period, representing a decline of 122.91% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CODX's revenue growth?

    In the latest financial report, Co-diagnostics, inc. (CODX) announced revenue of 263.92K, with a Year-Over-Year growth rate of 76.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CODX have?

    As of the end of the reporting period, Co-diagnostics, inc. (CODX) had total debt of 1.24M, with a debt ratio of 0.05. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CODX have?

    At the end of the period, Co-diagnostics, inc. (CODX) held Total Cash and Cash Equivalents of 11.88M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CODX go with three margins increasing?

    In the latest report, Co-diagnostics, inc. (CODX) did not achieve the “three margins increasing” benchmark, with a gross margin of 46%%, operating margin of -10,056.68%%, and net margin of -9,755.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CODX's profit trajectory and future growth potential.

  • Is CODX's EPS continuing to grow?

    According to the past four quarterly reports, Co-diagnostics, inc. (CODX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -16.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CODX?

    Co-diagnostics, inc. (CODX)'s Free Cash Flow (FCF) for the period is -6.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 23.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CODX?

    The latest valuation data shows Co-diagnostics, inc. (CODX) has a Price-To-Earnings (PE) ratio of -0.14 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.